Search continues for a treatment that reduces long COVID symptoms
The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine. The study, published Sept. 1 in eClinicalMedicine, details an international, multicenter phase 2/3 clinical trial that found a combination of amubarvimab and romlusevimab did not reduce the occurrence of long COVID symptoms.
Lasting weeks or even months after SARS-CoV-2 infection, long COVID is characterized by a variety of symptoms that affect each person differently. These include extreme fatigue, difficulty concentrating, ...










